Cancer (All Major Types)

Normally, cells grow, divide, and die in an orderly way, with the body replacing them as needed. In cancer, that orderly process breaks down: abnormal cells survive when they should die and form when they aren't needed, often building up into a mass called a tumor. Cancer is not a single disease but a large family of related diseases, and the National Cancer Institute notes there are more than 100 distinct types. Each behaves differently depending on the cell and tissue where it began. Because of this diversity, cancers are studied, named, and treated according to their origin rather than as one condition.

Cancer is fundamentally a genetic disease, caused by changes to the genes that govern how cells grow and divide. These changes can be inherited, can arise from errors during cell division, or can result from damage by things like tobacco smoke or ultraviolet light. The National Cancer Institute describes three main groups of genes involved: proto-oncogenes (which, when altered, can drive uncontrolled growth as oncogenes), tumor suppressor genes (which normally restrain growth), and DNA repair genes (which fix mistakes). When several of these controls fail, a cell can multiply unchecked. The body usually eliminates damaged cells, but this ability tends to decline with age.

A tumor is simply a lump of tissue, and it may be benign (not cancer) or malignant (cancer). Benign tumors do not invade nearby tissue and do not spread to other parts of the body, and once removed they usually do not grow back. Malignant tumors can grow into surrounding tissues and can shed cells that travel to distant sites. Benign tumors are usually not dangerous, though some can grow quite large or cause problems by pressing on nearby structures, such as in the brain. The key distinction is the ability to invade and spread, which defines a cancer.

The place where a cancer first forms is called the primary cancer. Cancer that has spread from there to another part of the body is called metastatic cancer, and the process of spreading is called metastasis. Importantly, metastatic cancer keeps the name and cell type of the original site: breast cancer that spreads to the lung is metastatic breast cancer, not lung cancer, and is treated as breast cancer. Cancer cells spread by breaking away from the original tumor and traveling through the blood or lymph system. Metastasis is the leading cause of death from cancer, which is why detecting and treating cancer before it spreads matters so much.

Although we use one word, cancer is really more than 100 different diseases grouped by the type of cell and tissue where they begin. A leukemia of the blood, a melanoma of the skin, and a carcinoma of the breast share the trait of uncontrolled growth but otherwise differ enormously in how they develop, spread, and respond to treatment. This is why two people described as having cancer may face completely different outlooks and care plans. Doctors classify cancers by their site of origin and their microscopic features, and increasingly by their specific gene changes. Understanding the exact type is the foundation of every treatment decision.

The World Health Organization reports that cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2022, or about one in six deaths globally. The most common new cancers worldwide that year were lung, breast, colorectal, prostate, and stomach cancers, while lung, colorectal, liver, breast, and stomach cancers caused the most deaths. WHO estimates that roughly one quarter of cancer deaths are linked to a small set of behaviors and exposures including tobacco, alcohol, high body weight, poor diet, and physical inactivity. Encouragingly, WHO also estimates that approximately 30 to 50 percent of cancers can currently be prevented. These figures describe global patterns and differ by country, sex, and age.

Carcinomas begin in epithelial cells, which form the skin and the linings of organs, glands, and body cavities. They are by far the most common group of cancers in adults. Subtypes are named for the epithelial cell of origin: adenocarcinomas arise from gland-forming (secretory) cells and are common in the breast, colon, prostate, lung, and pancreas; squamous cell carcinomas arise from flat lining cells found in skin, lung, and other surfaces. Other carcinoma types include transitional cell carcinoma (often in the bladder) and basal cell carcinoma of the skin. Because so many major organs are lined by epithelium, carcinomas account for most solid tumors.

Sarcomas arise in the body's connective and supportive tissues, including bone, cartilage, fat, muscle, blood vessels, and other fibrous tissue. They are broadly divided into bone sarcomas (such as osteosarcoma) and soft tissue sarcomas (such as liposarcoma or leiomyosarcoma). Sarcomas are much less common than carcinomas and can occur almost anywhere in the body. Because they are rare and diverse, they are often managed at specialized centers. The shared feature is that they originate in tissues that support and connect rather than in linings or glands.

Leukemias begin in the blood-forming tissue of the bone marrow and usually do not form solid tumors. Instead, abnormal blood cells build up in the marrow and bloodstream, crowding out healthy cells. They are classified along two axes: how quickly they progress (acute versus chronic) and the cell line involved (lymphocytic/lymphoblastic versus myeloid/myelogenous). This gives four common main types: ALL, AML, CLL, and CML. Symptoms can include fatigue, infections, and easy bruising or bleeding because normal blood cell production is disrupted.

Lymphomas begin in lymphocytes (a type of white blood cell) and tend to collect in lymph nodes, the spleen, and other lymphatic tissue. There are two broad categories: Hodgkin lymphoma, defined by the presence of distinctive Reed-Sternberg cells, and non-Hodgkin lymphoma, a large and varied group that is far more common. Non-Hodgkin lymphomas are further divided into B-cell and T-cell types and into slow-growing (indolent) and fast-growing (aggressive) forms. The distinction matters because Hodgkin and non-Hodgkin lymphomas, and their subtypes, are treated differently. A swollen but painless lymph node is a common way they first come to attention.

Multiple myeloma begins in plasma cells, a type of immune cell in the bone marrow that makes antibodies, and it can affect bones and blood throughout the body. Melanoma starts in melanocytes, the cells that make the pigment melanin, and most often arises in the skin but can occur in the eye and elsewhere. Brain and spinal cord (central nervous system) tumors are named for the cell type and where they form; gliomas are a common example, and these tumors may be benign or malignant but can be serious due to their location. Germ cell tumors begin in the cells that form sperm or eggs and most often arise in the testicles or ovaries. Each of these groups is defined by its originating cell, which guides how it is diagnosed and treated.

By body site, a few cancers dominate the numbers. Breast cancer, most often an adenocarcinoma of the milk ducts or lobules, is the most commonly diagnosed cancer in women and can rarely affect men. Lung cancer is divided into non-small cell lung cancer (NSCLC, about 80-85% of cases, including adenocarcinoma and squamous cell types) and small cell lung cancer (SCLC), which grows faster; it is a leading cause of cancer death worldwide. Prostate cancer, an adenocarcinoma of the prostate gland, is among the most common cancers in men. Colorectal cancer arises in the colon or rectum, usually from adenomatous polyps that can be found and removed by screening before they become cancer.

Skin cancers include the very common basal and squamous cell carcinomas and the more dangerous melanoma. Urinary tract cancers include bladder cancer (often transitional/urothelial) and kidney cancer (most commonly renal cell carcinoma). Digestive cancers include pancreatic cancer (often aggressive), liver cancer (frequently linked to chronic hepatitis), and esophageal and stomach cancers. Gynecologic cancers include ovarian, cervical (strongly linked to HPV), and endometrial (uterine) cancers. Thyroid cancer, which is frequently very treatable, rounds out the commonly listed sites. Each of these is named for its organ of origin and has its own typical behavior, screening picture, and outlook.

A risk factor is anything that increases the likelihood of developing a disease, but having one, or even several, does not guarantee cancer will occur, and many people with cancer had no obvious risk factors. Risk factors can be unchangeable, such as age and inherited genes, or modifiable, such as tobacco use, alcohol, and body weight. Cancer usually results from a combination of factors acting over many years, not a single cause. This is why doctors talk about increasing or decreasing risk rather than certainty. Understanding the difference helps people make informed choices without assuming blame or fatalism.

Cancer can occur at any age, but the risk for most types rises sharply as people get older, and many cancers are diagnosed in people in their sixties and beyond. This happens because gene-damaging changes accumulate over a lifetime, and the body's ability to repair or remove damaged cells declines with age. Age is not something that can be changed, but it helps explain why screening programs are often timed to begin at certain ages. Childhood cancers also occur but are far less common and tend to be biologically different. Age is therefore a central, though unmodifiable, part of cancer risk.

Tobacco is the single largest preventable cause of cancer; the WHO links tobacco use to a large share of cancer deaths, and it causes not only lung cancer but cancers of the mouth, throat, bladder, pancreas, and more. Alcohol is a known carcinogen and raises the risk of cancers of the mouth, throat, esophagus, liver, breast, and colon, with risk rising as intake rises. Ultraviolet (UV) radiation from the sun and tanning beds is the main cause of skin cancers, including melanoma. Ionizing radiation, such as high doses from certain sources, can also damage DNA and increase risk. Because these exposures are largely modifiable, they are central targets for cancer prevention.

A number of long-term infections are linked to cancer. Human papillomavirus (HPV) is a necessary cause of nearly all cervical cancers and contributes to anal, throat, and other cancers. Helicobacter pylori, a stomach bacterium, is a major cause of stomach cancer. Chronic hepatitis B and hepatitis C infections are leading causes of liver cancer, and Epstein-Barr virus (EBV) is linked to certain lymphomas and nasopharyngeal cancer. WHO estimates infections account for a meaningful share of cancers, especially in lower-income countries. Several of these are preventable through vaccination (HPV, hepatitis B) or treatable (H. pylori, hepatitis C), which is why they are important public-health targets.

Most cancers are not inherited, but about 5-10% are linked to harmful gene variants passed from parent to child. Inherited changes in the BRCA1 and BRCA2 genes substantially raise the lifetime risk of breast and ovarian cancer, and also affect risk of prostate, pancreatic, and other cancers. Lynch syndrome, caused by changes in mismatch repair genes, is the most common cause of hereditary colorectal and endometrial cancer. People with a strong family history or known syndrome may be offered genetic counseling, testing, earlier or more frequent screening, and risk-reducing options. Identifying an inherited risk can also help relatives understand their own risk.

Carrying excess body weight is linked to a higher risk of at least a dozen cancers, including colorectal, breast (after menopause), endometrial, kidney, and pancreatic cancers. Diets low in fruits and vegetables and high in processed foods, along with physical inactivity, also contribute to risk, often through their effect on weight and metabolism. Environmental and workplace exposures, such as air pollution, asbestos, and radon, can raise risk as well. WHO groups tobacco, alcohol, high body weight, low fruit and vegetable intake, and inactivity together as behaviors tied to roughly a quarter of cancer deaths. Because these factors are modifiable, they are a major focus of prevention advice.

WHO estimates that roughly 30-50% of cancers could be prevented by reducing known risk factors and applying existing prevention strategies. Not smoking, limiting alcohol, staying active, maintaining a healthy weight, and protecting skin from UV are core steps. Vaccines against HPV and hepatitis B prevent the infections that cause cervical, liver, and other cancers. Screening tests such as mammograms, cervical (Pap/HPV) tests, and colonoscopy or stool-based tests can find cancer early or detect precancerous changes before they become cancer, which can lower deaths from these cancers. Screening recommendations vary by age and individual risk and are set by organizations such as the American Cancer Society.

Staging is the process of finding out how much cancer there is and whether it has spread from where it started. Doctors use information from physical exams, imaging, biopsies, and sometimes surgery to assign a stage. Staging matters because it helps the care team plan treatment, estimate prognosis (the likely course), and compare results across patients and studies. A cancer's stage is generally set at diagnosis and, by convention, does not change even if the cancer later grows or shrinks, though doctors may restage if needed. Knowing the stage is one of the most important pieces of information after diagnosis.

The TNM system, maintained by the American Joint Committee on Cancer (AJCC) and the Union for International Cancer Control, is the most common staging system for solid tumors. T describes the size or extent of the primary tumor (for example T1 to T4, with higher numbers meaning larger or more invasive). N describes whether and how much the cancer has spread to nearby lymph nodes (N0 to N3). M describes whether the cancer has spread, or metastasized, to distant parts of the body (M0 for no, M1 for yes). These letters and numbers are then combined to produce an overall stage. Some cancers, such as blood cancers and brain tumors, use different staging approaches.

For many cancers, the TNM categories are combined into an overall stage written as a number from 0 to IV. Stage 0 is carcinoma in situ, meaning abnormal cells are present only in the layer where they began and have not invaded nearby tissue. Stages I, II, and III generally indicate larger tumors or greater spread to nearby tissue and lymph nodes, with higher numbers meaning more extensive disease. Stage IV means the cancer has spread to distant parts of the body. As a rule, a lower stage means the cancer has spread less and a higher stage means it has spread more. The same stage number can mean different things in different cancer types.

Grade is different from stage: it describes how much the cancer cells resemble normal cells when viewed under a microscope. Well-differentiated (low-grade) cells look close to normal and tend to grow and spread more slowly, while poorly differentiated or undifferentiated (high-grade) cells look very abnormal and tend to grow and spread faster. Pathologists assign grade using systems specific to each cancer type, such as the Gleason score for prostate cancer or grading for breast cancer. Grade is one factor, alongside stage and increasingly biomarkers, that helps predict behavior and guide treatment. A higher grade generally suggests a more aggressive cancer.

Beyond the cancer itself, doctors consider a person's overall ability to function, called performance status. It rates how well someone can perform everyday tasks, from being fully active to needing complete assistance, using scales such as the ECOG scale (0 to 5) or the Karnofsky scale (0 to 100). Performance status helps the care team judge whether a person is likely to tolerate intensive treatments and is often used to guide treatment choices and eligibility for clinical trials. It complements stage and grade by reflecting the whole person, not just the tumor. Two people with the same stage may receive different recommendations partly because of differing performance status.

In most cases, a definite cancer diagnosis requires a biopsy, the removal of a small sample of tissue or cells that a pathologist then examines under a microscope. Imaging and blood tests can strongly suggest cancer, but looking at the actual cells is what confirms whether cancer is present and what type it is. Biopsies can be done with a needle, through an endoscope, or by surgery, depending on where the suspicious area is. The same sample is often used for further testing of the cancer's grade and biomarkers. Because it identifies the exact cell type, the biopsy is the foundation of the diagnosis and treatment plan.

Imaging tests use energy such as X-rays, sound waves, magnetic fields, or radioactive tracers to create pictures of the inside of the body. X-rays and CT scans use radiation to show structures, with CT giving detailed cross-sectional images. MRI uses magnetic fields and is especially useful for soft tissues such as the brain and spinal cord. Ultrasound uses sound waves and is often used for organs like the breast, liver, and ovaries. PET scans use a small amount of radioactive sugar to highlight metabolically active areas and are frequently combined with CT (PET/CT). Imaging helps find tumors, guide biopsies, stage cancer, and monitor response to treatment, but it usually cannot confirm cancer on its own.

Tumor markers are substances, often proteins, made by cancer cells or by the body in response to cancer, and they can sometimes be measured in blood, urine, or tissue. Examples include PSA in prostate cancer, CA-125 in ovarian cancer, and CEA in colorectal cancer. These markers are mainly used to help monitor treatment, watch for recurrence, or support a diagnosis, but most are not specific or sensitive enough to diagnose cancer by themselves. General blood tests, such as a complete blood count, can also reveal clues, especially in blood cancers like leukemia. Results are interpreted alongside imaging, biopsy, and the clinical picture rather than in isolation.

Endoscopy lets doctors look directly inside hollow organs and body cavities using a thin, flexible tube with a light and camera. Different versions target different areas: colonoscopy examines the colon and rectum, upper endoscopy looks at the esophagus and stomach, and bronchoscopy examines the airways. Besides viewing suspicious areas, endoscopy allows the doctor to take biopsy samples or remove small growths such as polyps during the same procedure. In screening contexts, colonoscopy can find and remove precancerous polyps before they become cancer. Endoscopy is therefore both a diagnostic tool and, in some cases, a way to prevent cancer.

Biomarker testing (also called molecular, genomic, or tumor profiling) looks for specific genes, proteins, or other features within a cancer to guide care. Examples include HER2 in breast and stomach cancer, EGFR and ALK changes in lung cancer, PD-L1 levels that can inform immunotherapy, and microsatellite instability (MSI) or mismatch repair status in colorectal and other cancers. These features can show whether a cancer is likely to respond to a targeted therapy or immunotherapy, and they may identify eligibility for clinical trials. Testing can use tissue from a biopsy or, increasingly, a blood sample (a liquid biopsy). This kind of testing is a key part of precision medicine, tailoring treatment to the individual cancer.

After a biopsy or surgery, a pathologist examines the tissue and writes a pathology report, which becomes a central document in the diagnosis. It typically states whether cancer is present, the cancer type and where it began, and the grade (how abnormal the cells look). For surgical samples it may also describe tumor size, whether the edges (margins) are free of cancer, and whether nearby lymph nodes are involved, all of which feed into staging. The report often includes biomarker results that guide treatment. Patients can request a copy of their pathology report and review it with their care team to understand their diagnosis.

When cancer is contained in one area, a surgeon may remove the tumor along with a margin of surrounding healthy tissue and sometimes nearby lymph nodes to check for spread. This is often called curative or potentially curative surgery. Surgery can be open (one larger incision) or minimally invasive (small incisions, sometimes robot-assisted), and the approach depends on the cancer type and location. Some operations remove the whole tumor; others have different goals. The care team weighs benefits against recovery and risks for each person. Surgery is frequently combined with radiation or drug therapy before or after the operation.

When a tumor is attached to or near a vital organ, removing the entire mass may not be safe. In these cases a surgeon may perform debulking, taking out as much of the tumor as possible. Reducing the bulk of the cancer can help other treatments such as chemotherapy or radiation work more effectively on what remains. Debulking is used in certain cancers, such as some advanced ovarian cancers, as part of a larger plan. It is not a stand-alone cure but one piece of a coordinated strategy. The goals and expected benefit are discussed by the treatment team in advance.

Palliative surgery aims to ease problems caused by cancer, such as pain, bleeding, or a blockage in the bowel or another passage. The goal is to improve quality of life and relieve distressing symptoms, not necessarily to remove all of the cancer. For example, surgery might relieve pressure a tumor is putting on the spinal cord or nerves. Palliative procedures can be part of care at any stage, alongside other treatments. They reflect a focus on how a person feels day to day. The care team helps decide whether the likely relief is worth the procedure.

External beam radiation therapy is the most common form of radiation and is delivered by a machine called a linear accelerator that directs beams precisely at the tumor. The radiation damages the DNA inside cancer cells so they can no longer grow and divide, and these cells die off over days to weeks. Treatment is usually given in small daily doses (fractions) over several weeks to spare healthy tissue. It is a local treatment, affecting mainly the area being aimed at. Modern planning and imaging help shape the dose to the tumor while limiting nearby tissue. It is used for many cancers, including breast, lung, prostate, and head and neck.

In brachytherapy, sealed sources of radiation such as seeds, ribbons, or capsules are placed in or near the tumor. Because the source sits so close to the cancer, it can deliver a high dose to the tumor while limiting exposure to surrounding healthy tissue. Some implants are temporary and removed after a set time; others are permanent but become less radioactive over time. It is used in cancers such as prostate, cervical, and some others. People may have specific safety instructions during the active period. Brachytherapy is sometimes combined with external beam radiation.

Stereotactic body radiation therapy (SBRT) and stereotactic radiosurgery (SRS) use many finely focused beams that converge on a small tumor with great accuracy. Despite the name, radiosurgery involves no cutting; it uses concentrated radiation instead. Because the dose is so precise, treatment is usually completed in one to a few sessions rather than weeks. It is used for small tumors in places like the brain, lung, spine, and liver, and sometimes for limited areas of spread. Precise imaging and positioning are essential to protect nearby healthy tissue. The approach is chosen based on tumor size, location, and overall plan.

Ablation treats a tumor where it sits, often without major surgery, using a needle-like probe guided by imaging. Radiofrequency or microwave ablation uses heat to destroy cancer cells, while cryoablation uses extreme cold to freeze them. These approaches are local treatments and are typically used for small tumors, such as certain liver, kidney, or lung cancers. Ablation may be an option when surgery is not ideal or to complement other treatments. The choice depends on the tumor's size, number, and location. A specialist such as an interventional radiologist or surgeon performs the procedure.

Local treatments such as surgery, radiation, and ablation act on a specific site, while systemic (drug) therapies travel through the bloodstream to reach cancer throughout the body. Many cancer plans combine these so each does what it does best. For example, radiation or chemotherapy may be given before surgery to shrink a tumor, or afterward to lower the chance of return. The sequence and combination are tailored to the cancer type, stage, and the person's health. No single order fits everyone. The aim is to use each tool where it adds the most benefit.

There is no one-size-fits-all cancer treatment; plans depend on the cancer type, stage, genetic features, and a person's overall health and preferences. Many decisions are made by a multidisciplinary team, sometimes through a tumor board where surgeons, medical and radiation oncologists, pathologists, radiologists, and others review a case together. This shared approach helps match the best mix of treatments to each situation. Patients are encouraged to ask about the goals of treatment and what to expect. Plans can also change as new information, such as how a tumor responds, comes in. Asking questions and seeking second opinions are part of normal, healthy decision-making.

Chemotherapy (chemo) uses drugs to destroy cancer cells, mainly by attacking cells that grow and divide quickly, which is a hallmark of cancer. Because it is cytotoxic to most rapidly dividing cells, it can also affect some healthy ones, such as those in hair follicles, the gut lining, and bone marrow, which is why side effects occur. Chemo is usually a systemic treatment, meaning it circulates in the bloodstream throughout the body. It is given in cycles, with treatment periods followed by rest periods so the body can recover. Chemo may be used alone or with surgery, radiation, or other drugs. The specific drugs and schedule depend on the cancer type and goals.

A chemotherapy cycle is a period of treatment followed by a period of rest. Cancer cells are often dividing at different times, so repeated cycles increase the chance of hitting them while they are vulnerable. The rest period also gives healthy tissues, especially the bone marrow that makes blood cells, time to recover. A cycle might last a few weeks, and a full course can involve several cycles. The exact number and spacing are planned for each person and cancer. Blood tests between cycles help the team decide whether to proceed on schedule.

Immunotherapy works with the body's own immune system to fight cancer rather than attacking cancer cells directly. Immune checkpoint inhibitors are a major type; they block proteins, such as PD-1, PD-L1, or CTLA-4, that normally keep immune cells in check, allowing T cells to recognize and attack tumors. Drugs in this class have shown lasting benefit in cancers such as melanoma, lung, and kidney cancer. Because they ramp up immune activity, they can cause immune-related side effects in which the immune system attacks healthy tissues. These reactions can affect organs like the skin, gut, lungs, or glands and need prompt medical attention. The class is well established, though research continues into new targets and combinations.

CAR T-cell therapy is a form of immunotherapy in which a person's T cells are collected, genetically modified in a lab to make a chimeric antigen receptor (CAR), and then grown and returned to the body. The CAR helps the T cells recognize a specific marker on cancer cells and attack them. It has produced strong responses in certain blood cancers, such as some leukemias and lymphomas, including in patients whose cancer returned after other treatments. Because it powerfully activates the immune system, it can cause serious side effects such as cytokine release syndrome and neurologic effects, so it is given at specialized centers with close monitoring. It is a newer, rapidly evolving area of treatment. Eligibility is limited to specific cancer types and situations.

Targeted therapy uses drugs designed to act on specific changes (biomarkers) inside or on cancer cells that help them grow and spread. Because it homes in on these targets, it can affect cancer cells more selectively than traditional chemotherapy. Examples of targets include HER2 in some breast and stomach cancers, EGFR and ALK in some lung cancers, and BRAF in some melanomas. Many targeted drugs are small molecules (often kinase inhibitors) or monoclonal antibodies. Testing the tumor for the relevant target usually guides whether a targeted drug is likely to help. Cancers can develop resistance over time, and this is an active, fast-moving area of research.

Some cancers, notably many breast and prostate cancers, depend on hormones such as estrogen or testosterone to grow. Hormone therapy (also called endocrine therapy) works by lowering hormone levels in the body or blocking hormones from acting on cancer cells. In breast cancer, this is used when tumors are hormone-receptor positive; in prostate cancer, treatments reduce or block androgens. It is a systemic treatment and may be used for months or years, sometimes alongside other therapies. Side effects often relate to lowered hormone levels, such as hot flashes, bone thinning, or fatigue. Whether hormone therapy fits depends on the cancer's hormone-receptor status.

Stem cell transplants, also called bone marrow transplants, replace blood-forming stem cells that are destroyed by high doses of chemotherapy or radiation. In an autologous transplant, a person's own stem cells are collected and returned afterward; in an allogeneic transplant, the cells come from a donor. They are used mainly for blood cancers such as leukemia, lymphoma, and multiple myeloma. With donor transplants, the new immune cells can also help fight remaining cancer, but they can attack the body in a complication called graft-versus-host disease. Transplants involve significant risks and a long recovery, so they are done at specialized centers. The decision depends on the cancer type, the person's health, and donor availability.

An antibody-drug conjugate (ADC) links a monoclonal antibody to a powerful chemotherapy-like agent. The antibody acts like a homing device, attaching to a specific marker on cancer cells, and then delivers the toxic payload more directly to those cells. The aim is to concentrate the drug at the tumor while limiting exposure to healthy tissue. ADCs are used in several cancers, including some HER2-positive breast cancers and certain other tumor types, and the field is expanding quickly. Because they still carry potent drugs, they can cause significant side effects that the care team monitors. This is an active and evolving area of cancer drug development.

Many cancer treatments, especially chemotherapy, lower your neutrophils (infection-fighting white blood cells), a state called neutropenia. When neutrophils are low, your body can't fight infection well, so a fever may be the first and sometimes the only sign that a serious infection is taking hold. The American Cancer Society notes that 100.4°F (38°C) is commonly used as the fever threshold, but you should ask your care team what counts as a fever for you. Infections can become life-threatening very quickly in people who are neutropenic, sometimes within hours. This is why a fever during chemotherapy is treated as a true emergency rather than something to watch and wait on. Care teams usually start antibiotics urgently, often before test results are back.

Sepsis happens when an infection triggers a body-wide reaction that can damage organs and drop blood pressure dangerously. People with cancer, especially those with low white blood cell counts, are at higher risk because their immune defenses are weakened. Warning signs can include a high fever or feeling very cold and shivery, a fast heartbeat, fast breathing, confusion or disorientation, clammy or mottled skin, and feeling more unwell than with an ordinary illness. Sepsis is a medical emergency where every hour matters, and survival depends on getting antibiotics and fluids quickly. Because the early signs can look like a bad infection, the American Cancer Society stresses acting fast rather than waiting to see if things improve.

Malignant (or metastatic) spinal cord compression happens when cancer in or near the spine puts pressure on the spinal cord and the nerves, stopping them from working normally. Cancer Research UK notes that pain is often the first symptom — typically new or worsening back or neck pain, sometimes felt like a band around the chest or belly. As pressure increases, people may develop weakness or heaviness in the legs (or arms), numbness or pins-and-needles, difficulty walking, or changes in bladder or bowel control such as not being able to pass urine or losing control. Cancers of the lung, breast, and prostate, and multiple myeloma, account for a large share of cases. Treatment is an emergency because acting early can prevent permanent weakness or paralysis.

The superior vena cava is the large vein that carries blood from the head, neck, arms, and upper chest back to the heart. SVC syndrome happens when a tumor (most often lung cancer or lymphoma) or a clot presses on or blocks this vein, causing blood to back up. According to Cancer.Net, this can lead to swelling of the face, neck, upper chest, and arms, along with shortness of breath, cough, and sometimes a feeling of fullness in the head, headache, or visual changes. Symptoms may come on gradually or quickly and often look worse when lying down or bending forward. While many cases build over days, rapid breathing trouble or swelling of the throat can become an emergency. Treatment depends on the cause and may include steroids, radiation, chemotherapy, or a stent to open the vein.

Tumor lysis syndrome happens when a large number of cancer cells die rapidly — usually soon after starting treatment — and spill their contents into the bloodstream faster than the body can clear them. This causes high levels of potassium, phosphate, and uric acid, and low calcium, which together can injure the kidneys and disturb the heart's rhythm. It is most common in fast-growing blood cancers such as some leukemias and lymphomas. Symptoms can include nausea and vomiting, low or no urine output, swelling, muscle cramps, irregular heartbeat, seizures, or feeling very unwell. Doctors anticipate TLS in high-risk patients and try to prevent it with fluids and medicines that lower uric acid, plus close blood monitoring around the start of treatment.

Hypercalcemia of malignancy is one of the more common metabolic emergencies in cancer, often seen in advanced disease or cancers that affect the bones such as breast cancer, lung cancer, and multiple myeloma. When calcium in the blood climbs too high, it affects the nerves, muscles, kidneys, and brain. Early symptoms can be vague — increased thirst, frequent urination, constipation, nausea, loss of appetite, and tiredness — which makes it easy to miss. As levels rise, people may become confused, drowsy, weak, or extremely dehydrated, and in severe cases it can affect the heart rhythm or lead to coma. Treatment usually involves intravenous fluids and medicines that lower calcium, alongside treating the underlying cancer.

People with cancer are more likely to form blood clots because cancer and some treatments make the blood clot more easily; the American Cancer Society notes that about 1 in 10 cancer patients develops a clot. A deep vein thrombosis (DVT) usually forms in a leg or arm and causes pain, swelling, redness, or warmth — often in just one limb. The danger is that part of the clot can break off and travel to the lungs, causing a pulmonary embolism (PE). PE signs include sudden shortness of breath, chest pain or discomfort (often worse with breathing), a fast or irregular heartbeat, sweating, coughing up blood, or a sudden feeling of panic. A PE can be life-threatening within minutes. Blood clots are often treated with blood-thinning medicines.

Immunotherapy drugs called immune checkpoint inhibitors work by unleashing the immune system against cancer, but the same immune activity can sometimes attack healthy tissues — these are called immune-related adverse events (irAEs). They can affect almost any organ: the bowel (severe or persistent diarrhea/colitis), lungs (cough, breathlessness from pneumonitis), liver, skin, hormone glands such as the thyroid or adrenal glands, and more. These reactions can appear during treatment or even weeks to months after it ends, and unlike many side effects they tend to need steroids or other medicines that calm the immune system rather than simply waiting them out. Mild symptoms can escalate, so care teams ask patients to report new symptoms early. Always tell any healthcare provider that you are receiving or recently received immunotherapy.

Cancer-related fatigue is a persistent sense of physical, emotional, or mental tiredness that rest may not fully relieve, and it is very common during and after treatment. It can stem from the cancer itself, treatments like chemotherapy or radiation, low blood counts, poor sleep, pain, stress, or nutrition. The care team may look for treatable causes, such as anemia, and address them. Gentle, regular activity, good sleep habits, balancing rest with light exercise, and managing stress can help many people. Counseling and relaxation techniques may also be useful. Telling the care team about fatigue is important so it can be evaluated and managed.

Some cancer treatments, especially certain chemotherapy drugs and radiation to some areas, can cause nausea and vomiting. Care teams use anti-nausea medicines (antiemetics), often given before treatment, to prevent symptoms rather than just treat them after they start. Different drugs work in different ways, and they may be combined for stronger protection. Eating small, bland meals, staying hydrated, and avoiding strong smells can also help. Uncontrolled vomiting can lead to dehydration, so persistent symptoms should be reported. Preventing nausea early is generally more effective than trying to stop it once severe.

Certain chemotherapy drugs, and radiation to the head, can cause hair to thin or fall out because they affect the fast-growing cells in hair follicles. Not all treatments cause hair loss, and the amount varies by drug and dose. Hair loss can affect the scalp as well as other parts of the body, and it is usually temporary, with regrowth often beginning a few weeks to months after treatment ends. Regrown hair can sometimes differ in texture or color at first. Gentle hair care, head coverings, and scalp-cooling in some settings may help people cope. The emotional impact is real, and support is available.

Chemotherapy and some other treatments can lower the number of neutrophils, a type of white blood cell that fights infection, a condition called neutropenia. With fewer of these cells, even a minor infection can become serious quickly. A fever during this time can be a medical emergency that needs urgent evaluation. Simple steps such as frequent handwashing, avoiding sick contacts, and good food and dental hygiene can lower risk. The care team monitors blood counts and may sometimes use medicines that help the body make more white cells. Knowing the warning signs and when to call the team is an important part of staying safe.

Anemia means having too few red blood cells, which carry oxygen through the body. It is common during cancer treatment and can cause fatigue, weakness, dizziness, paleness, or feeling short of breath. The care team checks for anemia with blood tests and looks at how low the count is and what is causing it. Depending on the situation, management may include treating an underlying cause, medicines that help the body make red blood cells, or a blood transfusion. Rest, balanced nutrition, and pacing activities can help with day-to-day symptoms. Reporting new or worsening tiredness helps the team respond appropriately.

Certain chemotherapy drugs and other treatments can damage peripheral nerves, leading to tingling, numbness, burning, pain, or weakness, most often in the hands and feet. This is called chemotherapy-induced peripheral neuropathy and it can affect balance, fine movements, and sensitivity to temperature. Symptoms may build up over the course of treatment and sometimes improve afterward, though they can linger. The care team monitors for neuropathy because it can sometimes guide dose decisions. Protecting the hands and feet, taking care to avoid falls, and reporting symptoms early are helpful. Several approaches may ease discomfort, and the team can advise on options.

Mucositis is inflammation and sores in the lining of the mouth and throat, caused by treatments such as some chemotherapy and radiation to the head and neck. These cells turn over quickly, so they are sensitive to treatment, leading to redness, soreness, or ulcers. Mouth sores can make eating, drinking, and swallowing painful and can raise the risk of infection. Gentle, regular mouth care, such as soft brushing and rinses the team recommends, can reduce problems. Soft, non-irritating foods and good hydration may help comfort. Reporting mouth pain or trouble eating lets the team offer relief and watch for infection.

Pain in cancer can come from the tumor itself, from treatments, or from procedures, and it varies widely from person to person. Most cancer pain can be managed using a stepwise plan that may include non-opioid medicines, opioids when needed, and other approaches such as nerve-targeted treatments, radiation for painful sites, or physical and psychological supports. Describing pain accurately, including how strong it is and what makes it better or worse, helps the team tailor treatment. Pain that is well controlled supports better sleep, mood, appetite, and daily function. Concerns about medicines, including worries about opioids, are common and worth discussing openly. The goal is comfort and quality of life, planned with the care team.

Cancer and its treatments can change appetite, taste, and the ability to eat through nausea, mouth sores, fatigue, or other effects. Maintaining nutrition and a healthy weight supports strength, recovery, and tolerance of treatment. Strategies such as eating small, frequent meals, choosing higher-calorie or higher-protein foods when appetite is low, and managing symptoms that interfere with eating can all help. A registered dietitian who works with cancer patients can give tailored guidance. Sometimes the team addresses specific problems, like swallowing difficulty or severe weight loss, with extra support. Talking with the care team about eating challenges helps catch problems early.

Lymphedema is swelling, usually in an arm or leg, that can happen when the lymph system is damaged by surgery to remove lymph nodes or by radiation. With drainage slowed, fluid builds up in the tissues, causing swelling, heaviness, or tightness. It can appear soon after treatment or develop later, so awareness over time matters. Management may include specialized therapy such as manual lymphatic drainage, compression garments, careful skin care, and exercises taught by a trained therapist. Early attention to changes tends to make management easier. People at risk are often taught what signs to watch for and steps to lower risk.

Certain cancer treatments, including some chemotherapy, radiation, and surgery, can affect the ability to have children later, in both men and women. Because some options work best before treatment begins, it helps to raise fertility questions early with the care team. Approaches may include freezing sperm, eggs, or embryos, and other methods depending on the person's age, situation, and cancer. Not everyone is affected the same way, and effects can be temporary or lasting. A fertility specialist can explain what is realistic for an individual. Even when time is short, asking about options before starting treatment is worthwhile.

A cancer diagnosis affects far more than the body. The National Cancer Institute describes a wide range of normal emotional responses, including shock, fear, anxiety, sadness, anger, and feeling out of control. These feelings can come and go throughout diagnosis, treatment, and beyond, and there is no single right way to feel. For some people, distress becomes strong or lasting enough to interfere with daily life, sleep, or relationships — and that is worth raising with the care team, because it can be helped. Distress is now considered something care teams should ask about and address, much like pain or nausea. Naming what you feel and knowing it is shared by many others is often the first step in coping.

Anxiety and depression are common in people affected by cancer, and they are real medical conditions — not just being negative. The National Cancer Institute notes that signs of depression can include lasting sadness, loss of interest in things once enjoyed, changes in sleep or appetite, and trouble concentrating, while anxiety can bring restlessness, a racing heart, and constant worry. Fear of recurrence — worry that the cancer will return — is especially common after treatment ends and can be triggered by scans, check-ups, or new aches. These feelings are treatable through talking therapies, support, and sometimes medication. Recognizing the symptoms matters, because untreated anxiety and depression can affect quality of life and even how well someone copes with treatment.

Deciding how and when to talk about cancer with family is personal, and there is no perfect script. The American Cancer Society suggests that being open tends to help relationships and reduces the strain of keeping secrets, while also respecting that some details are yours to share when you're ready. With children, explanations work best when they match the child's age and use simple, honest words — including the word cancer — because children often sense when something is wrong and may fill the silence with frightening guesses. Reassuring children that the illness is not their fault, that it isn't contagious, and that they will be cared for can ease their worry. Keeping some routine and inviting questions over time, rather than in one big talk, helps families adjust together.

Support groups bring together people facing similar experiences, whether in person, by phone, or online. The American Cancer Society describes how they can help people feel less alone, share coping strategies, and hear how others have handled treatment decisions, side effects, and the emotional ups and downs. Groups vary widely — some are led by trained professionals, others by peers; some focus on a specific cancer type, age group, or caregivers. They are not a substitute for medical care or therapy, but many people find them a valuable complement. If a group doesn't feel like the right fit, it's perfectly reasonable to try another format or setting, and online communities can be useful for those who can't travel.

Psycho-oncology is the field focused on the emotional, social, and psychological side of cancer care. The American Cancer Society notes that psychosocial support, such as therapy and counseling, can help patients and caregivers cope with the emotional, mental, and social challenges of cancer. A range of professionals may be involved: clinical psychologists and psychiatrists, oncology social workers, counselors, and palliative care specialists, and some people also draw support from chaplains or religious counselors. Help can take many forms, including individual talk therapy, couples or family sessions, stress and relaxation techniques, and, when appropriate, medication for anxiety or depression. Asking the care team for a referral is a normal part of cancer care, not a last resort.

Cancer can bring practical strains alongside the emotional ones: time off work, travel to appointments, childcare, and the cost of treatment and medicines. The National Cancer Institute points patients toward support for these challenges, sometimes called financial toxicity, and encourages people to raise money worries early with their care team. Hospitals often have oncology social workers or financial counselors who can explain bills, check insurance coverage, and connect people to assistance programs, charities, or help with transportation and lodging. Asking for this help is common and can relieve stress that otherwise adds to the illness. Keeping records of expenses and asking about programs up front can make a real difference.

Family and friends who care for someone with cancer often carry a heavy load, managing appointments, medicines, household tasks, and emotional support, sometimes while holding down a job. The National Cancer Institute recognizes that caregivers commonly experience stress, fatigue, anxiety, and feelings of isolation, and research finds their distress levels can mirror those of the patient. Caregivers cope better when they accept help from others, take breaks, attend to their own health and feelings, and use support resources such as caregiver groups or counseling. Looking after yourself is not selfish — running on empty makes it harder to care for someone else. Many cancer centers offer resources aimed specifically at caregivers.

Survivorship covers life during and after cancer treatment, and for many people the period after active treatment ends brings unexpected emotions — relief mixed with anxiety, and the loss of the routine and reassurance that frequent appointments provided. The National Cancer Institute describes survivorship care as including follow-up visits to watch for recurrence, managing any lingering or new side effects, and attention to overall health and wellbeing. A survivorship care plan — a summary of the treatment received plus a schedule for follow-up and what to watch for — can help survivors and their other doctors coordinate ongoing care. Healthy habits, regular check-ups, and knowing which symptoms to report are central. Emotional support remains important in this phase, not just during treatment.

Cancer treatments can save lives but sometimes leave lasting marks on the body. The National Cancer Institute distinguishes long-term effects (side effects that begin during treatment and continue afterward) from late effects (problems that show up months or years later). Depending on the treatment, these can include fatigue, heart or lung changes, nerve problems (neuropathy), bone thinning, fertility or hormonal changes, memory and concentration difficulties sometimes called chemo brain, and a small increased risk of second cancers. Knowing your personal risk — based on the specific treatments you had — helps you and your doctors watch for and manage these effects early. This is one reason a written summary of past treatment is so useful for long-term care.

Palliative care is specialized care aimed at improving quality of life for people with a serious illness by treating symptoms such as pain, nausea, breathlessness, fatigue, and the emotional and practical strain of cancer. A common misconception is that it is only for the end of life — but the National Cancer Institute is clear that palliative care may be provided at any point in cancer care, from diagnosis onward, and can be given alongside treatments intended to cure or control the cancer. It is delivered by a team that may include doctors, nurses, social workers, chaplains, psychologists, and others who address the whole person. Receiving palliative care does not mean giving up on treatment. Many people find it helps them feel better and cope more fully throughout their cancer journey.

Hospice is a type of care for people in the later stages of a life-limiting illness, when treatments aimed at curing the cancer are no longer the goal. The National Cancer Institute explains that, unlike palliative care which can begin at any stage, hospice care starts when curative treatment is stopped and the sole focus becomes comfort and quality of life. Hospice teams manage pain and other symptoms, and they support the whole family emotionally, practically, and spiritually; care is often provided at home, but can also be given in hospices, hospitals, or care facilities. Choosing hospice is a deeply personal decision, and it is about living as fully and comfortably as possible in the time that remains — not about giving up. Hospice also typically offers bereavement support to families afterward.

Advance care planning means deciding, ahead of time, what kinds of medical care you would or would not want if you became too unwell to make decisions in the moment. The National Cancer Institute describes tools such as advance directives — including a living will (your wishes about treatments like resuscitation or life support) and a durable power of attorney for health care (naming someone you trust to speak for you). Talking openly with loved ones and your care team, and putting wishes in writing, can reduce uncertainty and ease the burden on family during a crisis. These plans can be revisited and changed at any time as your situation or feelings evolve. Having these conversations early, while well, is often easier than waiting for an emergency.

Near the end of life, the focus of care is on comfort and dignity, and a major part of that is controlling pain and other symptoms such as breathlessness, nausea, restlessness, and anxiety. The National Cancer Institute explains that effective treatments exist for most of these, including pain medicines (such as opioids when needed), and that fears about addiction should not stand in the way of relieving suffering in this setting. Care teams adjust medicines carefully to keep a person as comfortable and alert as the person wishes. Emotional, spiritual, and family support are part of this care too, and goals are guided by what matters most to the patient. Open conversations with the care team about wishes and worries help ensure comfort is prioritized.